The pharmaceutical and healthcare sector is one of the world’s most vital and innovative.
Against a backdrop of technological change and an increasing and aging population, we partner with our clients to help them achieve their goals, capitalise on opportunities and navigate uncertainty.
Combining deep scientific, technical and strategic knowledge we help our clients by providing the commercial nous, experience and range of services that only a large international professional services firm can offer, to anticipate and deliver innovative and value-enhancing solutions.
Representing Gilead in the successful defence of claims for patent infringement in both the UK and Australia brought by Idenix. These claims related to Gilead’s cure for Hepatitis C, sofosbuvir, worth over $10 billion in worldwide annual sales
Representing Ariosa, a subsidiary of Roche, in patent infringement proceedings brought against it in both the English High Court and the Australian Federal Court in relation to its Harmony® non-invasive prenatal test
Advising Diageo in relation to product liability issues arising from the distribution of Thalidomide in the late 1950s/early 1960s.
BioPharma Credit PLC
Advising BioPharma Credit PLC, a new listed investment fund managed by Pharmakon Advisors LP and investing in the life sciences industry, on its proposed IPO and listing on the London Stock Exchange
A global manufacturer of medical and pharmaceutical devices
A global manufacturer of medical and pharmaceutical devices in response to a ‘whaling’ attack that led to large sums of money being taken out of the company. We conducted a forensic investigation and advised on the freezing of the accounts and recovery of funds in European and Asian jurisdictions
a global pharmaceuticals company
Advising a global pharmaceuticals company on the business critical implementation of the EU General Data Protection Regulation (GDPR) across Europe. The EU GDPR will apply from 25 May 2018 to all EEA countries, and aims to harmonise data protection procedures and enforcement across the EU.
Alan specialises in public and private cross-border mergers and acquisitions, restructurings, joint ventures and partnership matters, acting for international corporates, investment banks and professional services firms.